8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A clinical deep-dive into the methodological gaps, enrollment biases, generalizability concerns, and conflict-of-interest issues in the SURPASS-2 head-to-head trial of tirzepatide vs semaglutide 1 mg.
A deep look at the SURPASS-2 randomization design, blinding strategy, estimand framework, comparator choice, and statistical approach, and what each decision means for how you should read the headline result.
A deep dive into cost-per-QALY models, payer-coverage realities, and individual patient value calculations derived from the SURPASS-2 head-to-head tirzepatide vs semaglutide 1 mg trial.
Deep dive into SURPASS-2 follow-up data on tirzepatide vs semaglutide 1 mg in type 2 diabetes, covering durability of A1C and weight effects, post-trial regression, and emerging safety signals.
A detailed breakdown of the SURPASS-2 trial results comparing tirzepatide vs semaglutide 1 mg in type 2 diabetes, including effect sizes, confidence intervals, secondary endpoints, and time-course patterns.
Deep-dive into SURPASS-2 pre-specified and post-hoc subgroup analyses comparing tirzepatide vs semaglutide 1 mg across age, sex, BMI, race, and baseline biomarkers in type 2 diabetes.
A plain-English deep dive into the SURPASS-2 trial comparing tirzepatide to semaglutide 1 mg in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
How the SURPASS-2 head-to-head trial of tirzepatide vs semaglutide 1 mg reshapes prescribing decisions, guideline updates, and real-world treatment selection for type 2 diabetes.